{"protocolSection": {"identificationModule": {"nctId": "NCT03722524", "orgStudyIdInfo": {"id": "IC4-06593-057-RUS"}, "organization": {"fullName": "Servier Russia", "class": "INDUSTRY"}, "briefTitle": "The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension", "officialTitle": "Multinational Observational Uncontrolled Open Programme \"The Use of TRIple Fixed-dose COmbination in the Treatment of arteriaL Hypertension: Opportunity for Effective BP Control With cOmbined Antihypertensive Therapy\"", "acronym": "TRICOLOR"}, "statusModule": {"statusVerifiedDate": "2021-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-10-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-07-17", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-07-17", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-10-22", "studyFirstSubmitQcDate": "2018-10-25", "studyFirstPostDateStruct": {"date": "2018-10-29", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-12-04", "resultsFirstSubmitQcDate": "2021-03-03", "resultsFirstPostDateStruct": {"date": "2021-03-30", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-05-27", "lastUpdatePostDateStruct": {"date": "2021-06-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Servier Russia", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The use of TRIple fixed-dose COmbination in the treatment of arteriaL hypertension: opportunity for effective BP control with cOmbined antihypertensive therapy.\n\nThe main aim of this study to assess the antihypertensive effectiveness effect on the 24-hour BP profile, as well as tolerability of and compliance to the treatment with a triple FDC of amlodipine / indapamide / perindopril arginine in hypertensive patients in the real clinical practice.\n\nType of program: Multicenter, observational, non-controlled, open-label program.\n\nInvestigators: Cardiologists and outpatient (primary care) physicians (general practitioners).\n\nNumber of patients: 1,300 hypertensive patients.", "detailedDescription": "It is multicenter, observational, non-controlled, open-label program. The baseline characteristics will be analyzed in all the patients who started the treatment (intention-to-treat \\[ITT\\] population). In case of significant differences between two treatment groups, the baseline characteristics will be provided for both of them.\n\nChanges in the SBP and DBP (with the corresponding confidence intervals) will be assessed in the patients who completed the program without major deviations from protocol (per-protocol population \\[PPP\\]).\n\nThe analysis of parameters with normal distribution will be performed using the Student's t-test for paired measurements; otherwise the non-parametric Wilcoxon test will be used. The percentage of patients with normalized BP, as well as the percentage of patients who responded to treatment (with 95% confidence intervals), will be calculated.\n\nQuestionnaires: The score for each scale will be calculated as the sum of scores for questions constituting the scale.\n\nAssessment of the AEs will be carried out in all the patients who started the treatment (ITT population)."}, "conditionsModule": {"conditions": ["Arterial Hypertension"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "OTHER", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1247, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with arterial hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.", "interventionNames": ["Drug: amlodipine / indapamide / perindopril arginine FDC"]}], "interventions": [{"type": "DRUG", "name": "amlodipine / indapamide / perindopril arginine FDC", "description": "CCB / diuretic / ACE inhibitor", "armGroupLabels": ["Patients with arterial hypertension"], "otherNames": ["CCB / diuretic / ACE inhibitor"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline", "description": "Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded.", "timeFrame": "Baseline, 3 months"}, {"measure": "The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.", "description": "Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position", "timeFrame": "Baseline, 3 months"}], "secondaryOutcomes": [{"measure": "Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline", "description": "The assessment of the target office BP levels (SBP \\<140 mm Hg and DBP \\<90 mm Hg) was performed in accordance with ESC Guidelines for the management of arterial hypertension (2013)", "timeFrame": "Baseline, 3 months"}, {"measure": "The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline", "description": "Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.\n\nThe SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.", "timeFrame": "Baseline, 3 months"}, {"measure": "The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline", "description": "Change in the mean score of the of the physical component of the SF-36 survey Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.\n\nThe SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.", "timeFrame": "Baseline, 3 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 to 79 years\n* Essential hypertension\n* Patient's consent to participate in the program\n* Doctor's decision to prescribe FDC of amlodipine / indapamide / perindopril arginine, according to the instruction for use, prior to the inclusion in the program.\n\nExclusion Criteria:\n\n* Symptomatic, or secondary arterial hypertension\n* Office BP \u2265 180/110 mm Hg on treatment (at V0 visit)\n* History of myocardial infarction, unstable angina, or cerebrovascular accident within the past 1 year\n* CHF of class III-IV NYHA\n* Type I diabetes or decompensated type 2 diabetes\n* Diseases with severe organ dysfunction (hepatic failure, renal failure, etc.)\n* Contraindications to or known intolerance of dihydropyridine calcium channel blockers (including amlodipine) and/or indapamide and/or ACE inhibitors (including perindopril) and/or their fixed combination\n* Inability to understand the nature of the program and/or to follow the doctor's recommendations, including ones for the BP self-monitoring.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Patients with uncontrolled arterial hypertension who needs triple antihypertensive combinations in a single tablet", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Natatya LOGUNOVA", "role": "STUDY_CHAIR"}], "locations": [{"facility": "City Policlinic #3", "city": "Almetyevsk", "country": "Russian Federation", "geoPoint": {"lat": 54.90442, "lon": 52.3154}}, {"facility": "City Policlinic # 9", "city": "Barnaul", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "City Policlinic # 7", "city": "Belgorod", "country": "Russian Federation", "geoPoint": {"lat": 50.61074, "lon": 36.58015}}, {"facility": "City Hospital # 2", "city": "Brjansk", "country": "Russian Federation", "geoPoint": {"lat": 53.25209, "lon": 34.37167}}, {"facility": "City Policlinic # 15", "city": "Chabarowsk", "country": "Russian Federation", "geoPoint": {"lat": 48.48271, "lon": 135.08379}}, {"facility": "City Policlinic # 8", "city": "Chelyabinsk", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "City Policlinic # 2", "city": "Cherepovets", "country": "Russian Federation", "geoPoint": {"lat": 59.13333, "lon": 37.9}}, {"facility": "City Policlinic # 3", "city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "City Policlinic # 8", "city": "Irkutsk", "country": "Russian Federation", "geoPoint": {"lat": 52.29778, "lon": 104.29639}}, {"facility": "City Policlinic # 5", "city": "Ivanovo", "country": "Russian Federation", "geoPoint": {"lat": 56.99719, "lon": 40.97139}}, {"facility": "City Hospital # 1", "city": "Izhevsk", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "City Policlinic # 1", "city": "Jaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "City Policlinic # 18", "city": "Kazan", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "City Policlinic # 5", "city": "Kemerovo", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "City Policlinic # 2", "city": "Kirov", "country": "Russian Federation", "geoPoint": {"lat": 58.59665, "lon": 49.66007}}, {"facility": "City Policlinic # 7", "city": "Krasnoyarsk", "country": "Russian Federation", "geoPoint": {"lat": 56.01839, "lon": 92.86717}}, {"facility": "City Policlinic # 7", "city": "Kursk", "country": "Russian Federation", "geoPoint": {"lat": 51.73733, "lon": 36.18735}}, {"facility": "FSBI NMIC of Cardiology of the Ministry of Health of Russia", "city": "Moscow", "zip": "121552", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "City Policlinic # 70", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "City Policlinic # 2", "city": "Murmansk", "country": "Russian Federation", "geoPoint": {"lat": 68.97917, "lon": 33.09251}}, {"facility": "City Policlinic # 17", "city": "Nizhniy Novgorod", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "City Hospital # 2", "city": "Novokuznetsk", "country": "Russian Federation", "geoPoint": {"lat": 53.7557, "lon": 87.1099}}, {"facility": "City Policlinic # 14", "city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "City Policlinic # 2", "city": "Omsk", "country": "Russian Federation", "geoPoint": {"lat": 54.99244, "lon": 73.36859}}, {"facility": "Clinic PROM-MED", "city": "Orenburg", "country": "Russian Federation", "geoPoint": {"lat": 51.7727, "lon": 55.0988}}, {"facility": "City Policlinic # 2", "city": "Or\u00ebl", "country": "Russian Federation", "geoPoint": {"lat": 52.96508, "lon": 36.07849}}, {"facility": "Policlinic of Regional Clinic Hospital", "city": "Penza", "country": "Russian Federation", "geoPoint": {"lat": 53.20066, "lon": 45.00464}}, {"facility": "Medical Center \"Alfa-Center\"", "city": "Perm", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "City Policlinic # 4", "city": "Petrozavodsk", "country": "Russian Federation", "geoPoint": {"lat": 61.78491, "lon": 34.34691}}, {"facility": "City Policlinic # 3", "city": "Pskov", "country": "Russian Federation", "geoPoint": {"lat": 57.8136, "lon": 28.3496}}, {"facility": "City Policlinic # 42", "city": "Rostov-on-Don", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "City Policlinic # 2", "city": "Ryazan'", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "City Policlinic # 8", "city": "Samara", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "City Policlinic # 27", "city": "Sankt-Peterburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "City Policlinic # 2", "city": "Saratov", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "City Policlinic # 2", "city": "Sevastopol", "country": "Russian Federation"}, {"facility": "Policlinic of Russian railway", "city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "City Policlinic # 2", "city": "Stary Oskol", "country": "Russian Federation", "geoPoint": {"lat": 51.29667, "lon": 37.84167}}, {"facility": "City Policlinic # 3", "city": "Syktyvkar", "country": "Russian Federation", "geoPoint": {"lat": 61.67642, "lon": 50.80994}}, {"facility": "City Policlinic # 6", "city": "Tambov", "country": "Russian Federation", "geoPoint": {"lat": 52.73169, "lon": 41.44326}}, {"facility": "City Policlinic # 3", "city": "Tjumen", "country": "Russian Federation", "geoPoint": {"lat": 57.15222, "lon": 65.52722}}, {"facility": "City Policlinic # 2", "city": "Toljatti", "country": "Russian Federation", "geoPoint": {"lat": 53.5303, "lon": 49.3461}}, {"facility": "City Policlinic # 2", "city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Policlinic VIRMED", "city": "Tula", "country": "Russian Federation", "geoPoint": {"lat": 54.19609, "lon": 37.61822}}, {"facility": "City Policlinic # 46", "city": "Ufa", "country": "Russian Federation", "geoPoint": {"lat": 54.74306, "lon": 55.96779}}, {"facility": "City Policlinic # 4", "city": "Veliky Novgorod", "country": "Russian Federation", "geoPoint": {"lat": 58.52131, "lon": 31.27104}}, {"facility": "City Policlinic # 4", "city": "Vladimir", "country": "Russian Federation", "geoPoint": {"lat": 56.13655, "lon": 40.39658}}, {"facility": "City Policlinic # 4", "city": "Vladivostok", "country": "Russian Federation", "geoPoint": {"lat": 43.10562, "lon": 131.87353}}, {"facility": "City Policlinic # 15", "city": "Volgograd", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "City Policlinic # 3", "city": "Vologda", "country": "Russian Federation", "geoPoint": {"lat": 59.2239, "lon": 39.88398}}, {"facility": "City Policlinic # 7", "city": "Voronezh", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1247"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1148"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "99"}]}], "dropWithdraws": [{"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "86"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Reason is not stated", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Patient's decision (refusal to continue participation)", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "810"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "338"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "59.24", "spread": "10.48"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "No gender was indicated for 10 patients", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1138"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "687"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "451"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1148"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Russia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1148"}]}]}]}, {"title": "Patients with arterial hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1148"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1148"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Mean Systolic BP Changes (mm Hg) at the Visit 4 vs. Baseline", "description": "Changes in the mean office systolic BP levels (in mm Hg) in the sitting position Blood pressure was measured in accordance with the guidelines of the European Society of Hypertension (ESH) using the auscultatory or oscillometric method and a semi-automated sphygmomanometer. Before taking measurements, the patient remained in a sitting position for 3-5 minutes. Blood pressure was determined on each arm, and the arm with the highest value was taken as the reference. Measurements were taken thrice in the sitting position of a patient, and the average of the second and third BP measurements on the reference arm with an interval of at least 1-2 minutes was recorded.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33.47", "spread": "11.70"}]}]}]}, {"type": "PRIMARY", "title": "The Mean Diastolic BP Changes (mm Hg) at the Visit 4 vs Baseline.", "description": "Changes in the mean office diastolic BP levels (in mm Hg) in the sitting position", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.34", "spread": "8.63"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved the Target Office BP Levels (SBP <140 mm Hg and DBP <90 mm Hg) at Visit 4 vs Baseline", "description": "The assessment of the target office BP levels (SBP \\<140 mm Hg and DBP \\<90 mm Hg) was performed in accordance with ESC Guidelines for the management of arterial hypertension (2013)", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of patients", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "93.38", "lowerLimit": "91.74", "upperLimit": "94.72"}]}]}]}, {"type": "SECONDARY", "title": "The Mean Standardized Score of the Physical Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline", "description": "Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.\n\nThe SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.64", "spread": "18.06"}]}]}]}, {"type": "SECONDARY", "title": "The Mean Standardized Score of the Mental Component of the Quality of Life Questionnaire The Short Form (36) Health Survey at Visit 4 vs Baseline", "description": "Change in the mean score of the of the physical component of the SF-36 survey Change in the mean score of the of the physical component of the The Short Form (36) Health Survey (SF-36) survey.\n\nThe SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline, 3 months", "groups": [{"id": "OG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "23.57", "spread": "13.79"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "10 months", "eventGroups": [{"id": "EG000", "title": "Patients With Arterial Hypertension", "description": "The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.\n\nPresumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients.\n\namlodipine / indapamide / perindopril arginine FDC: CCB / diuretic / ACE inhibitor", "deathsNumAffected": 0, "deathsNumAtRisk": 1148, "seriousNumAffected": 3, "seriousNumAtRisk": 1148, "otherNumAffected": 9, "otherNumAtRisk": 1148}], "seriousEvents": [{"term": "tooth abscess", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "for which the surgical treatment was performed", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}, {"term": "exacerbation of chronic pyelonephritis", "organSystem": "Immune system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "which was stopped by administration of antibiotics)", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}, {"term": "unstable angina", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}], "otherEvents": [{"term": "arterial hypotension with BP of 80/50 mm Hg and weakness", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}, {"term": "treatment inefficacy", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}, {"term": "unstable angina", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}, {"term": "cough", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 1148}]}, {"term": "arterial hypotension", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 1148}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Natalya LOGUNOVA", "organization": "AO Servier", "email": "Natalya.LOGUNOVA@servier.com", "phone": "+7 495 9370700"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-06-25", "uploadDate": "2020-12-04T05:18", "filename": "Prot_SAP_000.pdf", "size": 1298006}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2018-06-25", "uploadDate": "2020-12-04T05:23", "filename": "ICF_001.pdf", "size": 452347}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000020913", "term": "Perindopril"}, {"id": "D000007190", "term": "Indapamide"}, {"id": "C000494243", "term": "Indapamide, perindopril drug combination"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "asFound": "G/kg", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M22648", "name": "Perindopril", "asFound": "Respond to", "relevance": "HIGH"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "asFound": "Skin biopsy", "relevance": "HIGH"}, {"id": "M10234", "name": "Indapamide", "asFound": "Pharmacologic", "relevance": "HIGH"}, {"id": "M181594", "name": "Indapamide, perindopril drug combination", "asFound": "Barrett's Epithelium", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "T1", "name": "Arginine", "asFound": "Every 21 days", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}